ProCE Banner Series

Navigating Modern Immunotherapeutic Approaches for Melanoma: Considerations for Oncology Pharmacists

Watch this webinar as melanoma expert pharmacists discuss the latest in immunotherapy for melanoma and the role of the oncology pharmacist in care.

  ACPE-P
Who Should Attend

This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders involved in the care of patients with melanoma.

All Events

Navigating Modern Immunotherapeutic Approaches for Melanoma: Considerations for Oncology Pharmacists

Upcoming Events

May

01

2024

1:00 PM - 2:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Colleen McCabe, PharmD, BCOP

Clinical Oncology Pharmacy Specialist, Sarcoma and Melanoma
Vanderbilt University Medical Center
Nashville, Tennessee

ProCE Banner Faculty
Jordan McPherson, PharmD, MS, BCOP

Interim Clinical Manager, Huntsman Cancer Institute
Oncology Clinical Pharmacist, Melanoma and Non-Melanoma Skin Cancers
Adjunct Associate Professor, University of Utah College of Pharmacy
Salt Lake City, Utah

Topics

  • Welcome and Introduction
  • Expert Discussion: Immunotherapeutic Strategies in the Adjuvant and Neoadjuvant Settings
  • Expert Discussion: Immunotherapeutic Strategies in Advanced Melanoma
  • Unpacking the Impact of Oncology Pharmacists in Optimizing Adverse Event Management
  • Closing Remarks and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Melanoma.

Target Audience
This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders involved in the care of patients with melanoma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Employ the latest guidelines and recent clinical trial findings regarding immunotherapy to aid personalize treatment selection for patients with melanoma in the adjuvant/neoadjuvant and metastatic settings
  • Select optimal immunotherapy treatment regimens and sequencing to maximize efficacy in patients with melanoma
  • Manage irAEs in patients with melanoma to ensure maximum benefit from immunotherapy with minimal treatment disruption

Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-24-005-L01-P has been assigned to this live application-based activity (initial release date 5/1/2024). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

Supported by an educational grant from Bristol-Myers Squibb.